The Technical Analyst
RespireRx Pharmaceuticals [RSPI]
Exchange: OTC Sector: Healthcare Industry: Biotechnology
RespireRx Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-18.18% $0.0009
America/New_York / 3 mai 2024 @ 15:55
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.329 mill |
| EPS: | -0.0200 |
| P/E: | -0.0400 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 365.42 mill |
| Avg Daily Volume: | 9.08 mill |
| RATING 2024-05-03 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0400 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0400 | industry: PE 136.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0009 - 0.0009 ( +/- 0.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2020-09-30 | Dickason David | Buy | 2 000 000 | Common Stock Options (to purchase shares of Common Stock) |
| 2020-09-30 | Jones Timothy L. | Buy | 4 409 063 | Common Stock |
| 2020-09-30 | Jones Timothy L. | Buy | 4 409 063 | Warrants (to purchase Common Stock) |
| 2020-09-30 | Jones Timothy L. | Buy | 4 409 063 | Common Stock |
| 2020-09-30 | Jones Timothy L. | Buy | 4 409 063 | Warrants (to purchase Common Stock) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 99 transactions |
| Buy: 326 429 999 | Sell: 11 508 564 |
Forecast:
16:00 - $0.0009
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.0009
Forecast 2: 16:00 - $0.0009
Forecast 3: 16:00 - $0.0009
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0009 (-18.18% ) |
| Volume | 5.71 mill |
| Avg. Vol. | 9.08 mill |
| % of Avg. Vol | 62.90 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RSPI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
RSPI
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.
Last 10 Buy Signals
Latest Press Releases
2024-03-20 08:30:00 - Press Release
Respirerx Pharmaceuticals Inc. Reports Publication Of Preclinical Research Results Demonstrating The Ability Of Cx1739, Its Lead Clinical Ampakine, To Improve Bladder Function After Spinal Cord Injury
Glen rock, n.j., march 20, 2024 (globe newswire) -- respirerx pharmaceuticals inc. (otc pink market: rspi) (“respirerx” or the “company”), focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that, as part of an ongoing collaboration, a scientist team led by dr. david fuller of the university of florida has published a peer-reviewed research article describing the ability of cx1739, the company's lead clinical-stage ampakine (ampa glutamate receptor potentiator), to restore bladder function in rodents that have undergone spinal cord injury (sci).
2024-02-13 08:30:00 - Press Release
Respirerx Pharmaceuticals Inc. Reports Preclinical Pain Relief For Their Non-opioid Lead Gabakine
Glen rock, n.j., feb. 13, 2024 (globe newswire) -- respirerx pharmaceuticals inc. (otc pink market: rspi) (“respirerx” or the “company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that krm-ii-81, its lead gabaa receptor potentiator (gabakine), has advanced to the next level of evaluation within the nih heal initiative® preclinical screening platform for pain (pspp) program.
2024-01-22 08:30:00 - Press Release
Respirerx Pharmaceuticals Inc. Announces The Appointment Of Dr. Dariusz Naziek To Its Board Of Directors
Glen rock, n.j., jan. 22, 2024 (globe newswire) -- respirerx pharmaceuticals inc. (otc pink market:rspi) (“respirerx” or the “company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the appointment of dr. dariusz nasiek md, mba to its board of directors. dr. nasiek is a dedicated anesthesiologist with expertise in anesthesiology and interventional pain management. dr. nasiek is board certified by the american board of anesthesiology, the american board of pain medicine and the american board of interventional pain physicians. dr. nasiek is also a life member of the american society of interventional pain physicians and a member of the international spine intervention society...
2024-01-04 08:45:00 - Press Release
Respirerx Pharmaceuticals Inc. Announces The Publication Of A Case Report In Which Krm-ii-81 Totally Suppressed Epileptiform Activity In Brain Tissue Surgically Removed From Epileptic Patient
Glen rock, n.j., jan. 04, 2024 (globe newswire) -- respirerx pharmaceuticals inc. (otc pink market: rspi) (“respirerx” or the “company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the publication of a case report in heliyon, cell press's peer-reviewed journal (available at https://www.cell.com/heliyon/pdf/s2405-8440(23)10960-1.pdf) involving a 19-year old patient with pharmaco-resistant epilepsy. as is often the case with such patients, tolerance developed to the standard anti-epileptic treatments, rendering them ineffective, and the patient required a craniotomy in order to remove the brain tissue responsible for the seizure generation...
2023-12-11 08:30:00 - Press Release
Respirerx Pharmaceuticals Inc. Announces Agreement With Ponto Ventures To Drive Business Development With Will Clodfelter As Respirerx Part-time Senior Vp Of Business Development
Glen rock, n.j., dec. 11, 2023 (globe newswire) -- respirerx pharmaceuticals inc. (otc pink market: rspi) (“respirerx” or the “company”), a biopharmaceutical company focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that, on december 6, 2023, it has entered into an agreement with ponto ventures llc providing for will clodfelter to serve as respirerx's senior vice president of business development on a part-time basis.
Latest News
2024-02-13 09:34:57 - Proactive Investors
RespireRx's key asset moves to next stage of NIH initiative
RespireRx Pharmaceuticals (OTC:RSPI) Inc, a pioneer in the field of neuronal signaling treatments, said its lead compound, KRM-II-81, has progressed to the next evaluation phase of the National Institutes for Health's HEAL Initiative's Preclinical Screening Platform for Pain (PSPP) program. In doing so the compound demonstrated efficacy in reducing pain-like behaviors in rat models, covering both male and female subjects across various pain measures, underlining its potential to treat acute, chronic, and neuropathic pain without leading to tolerance or sedation.
2024-01-22 09:17:55 - Proactive Investors
RespireRx Pharmaceuticals strengthens board, adding new director
RespireRx Pharmaceuticals (OTC:RSPI) has strengthened its board, with the appointment of Dr Dariusz Nasiek as a director. The drug discovery firm focussed on psychiatric and neurological disorders, in a statement, said that Nasiek brings valuable experience to the board with his background in both medicine and business.
2024-01-04 09:34:59 - Proactive Investors
RespireRX Pharmaceuticals reports ‘highly encouraging' case study results for KRM-II-81
RespireRx Pharmaceuticals (OTC:RSPI) said a case study demonstrating positive results from the treatment of an epilepsy patient involving its therapeutic KRM-II-81 has been published in a peer-reviewed journal. The company said that the 19-year-old patient in the case study had pharmaco-resistant epilepsy and required a craniotomy to remove the brain tissue generating seizures.
2023-12-11 09:37:03 - Proactive Investors
RespireRX Pharmaceuticals announces Ponto Ventures' MD Will Clodfelter will help drive business development
RespireRx Pharmaceuticals (OTC:RSPI) has announced an agreement with Ponto Ventures LLC under which Will Clodfelter will serve as its senior vice president of business development on a part-time basis. Clodfelter is the founder and managing director of Ponto Ventures, a biotech and device strategy consulting firm.
2023-10-12 09:38:09 - Proactive Investors
RespireRx Pharmaceuticals subsidiary inks MSA for dronabinol manufacturing
RespireRx Pharmaceuticals (OTC:RSPI) Ltd and its ResolutionRx subsidiary announced that it has entered into a Master Services Agreement (MSA) with Australia's Ab Initio Pharma Pty Ltd (Ab Initio), under which Ab Initio will manufacture, formulate, test and supply ResolutionRx with therapeutic drugs based on lipid nanoparticle technology licensed from RespireRx. The biopharma company said the initial services relate to ResolutionRx's repurposing of dronabinol and its development program for obstructive sleep apnea pursuant to which Ab Initio will, among other things, manufacture and test its new dronabinol lipid nanoparticle formulation for pharmacokinetic, pharmacodynamic, and pivotal clinical trials, as well as ultimately for commercialization.
2023-05-24 09:41:51 - Proactive Investors
RespireRx Pharmaceuticals' Australia cannabis subsidiary inks LOI securing $3.1M investment
RespireRx Pharmaceuticals (OTC:RSPI) Inc subsidiary ResolutionRx Ltd entered into a binding letter of intent last week with Cantheon Capital, in which the latter would help fund the former's clinical trial research and development. The letter describes a total investment of $3.125 million by Cantheon in Australian Series A Preference Shares issued by ResolutionRx.
2023-04-03 10:06:17 - Proactive Investors
RespireRx Pharmaceuticals highlights analogs of its anti-seizure treatment in scientific publications
RespireRx Pharmaceuticals (OTC:RSPI) Inc has announced the publication of four articles describing the pharmacological activity of novel structural analogs of KRM-II-81, the company's lead anti-GABAkine. Like RespireRx's KRM-II-81, the analogs enhance GABAergic neurotransmission and function as orally bioavailable anti-seizure agents in the absence of the sedation typically associated with GABA augmentation.
2023-03-28 09:54:55 - Proactive Investors
RespireRx Pharmaceuticals appoints Joseph Siegelbaum as independent director on its board
RespireRx Pharmaceuticals (OTC:RSPI) Ltd has announced the appointment of Joseph Siegelbaum to the company's board as an independent director, effective March 22, 2023. The biopharma firm said Siegelbaum, a former partner at the law firm of Goodwin Procter LLP in New York until his retirement at the end of 2021, served as a member of the board of directors and president of the New York March of Dimes from 2004 through 2022.
2023-03-01 09:35:56 - Proactive Investors
RespireRx Pharmaceuticals' Australian subsidiary ResolutionRx enters services agreement with CRO iNGENu
RespireRx Pharmaceuticals (OTC:RSPI) Ltd and its wholly-owned unlisted Australian subsidiary ResolutionRx Ltd jointly announced that ResolutionRx has entered into a services agreement for clinical research and other related services with Melbourne, Australia-based contract research organization (CRO) iNGENu. The companies said in a statement that under the agreement, iNGENu will act as a full-service CRO in support of ResolutionRx's research and development program, which is developing a proprietary formulation of dronabinol for the treatment of obstructive sleep apnea and anorexia.
2023-02-01 09:41:08 - Proactive Investors
RespireRx Pharmaceuticals' Australian subsidiary inks loan agreements to advance R&D for sleep apnea treatment
RespireRx Pharmaceuticals (OTC:RSPI) Inc announced that its recently created Australia-based subsidiary ResolutionRx Ltd has signed a letter of intent (LOI) and term sheet with Radium Capital. The agreements cover a series of planned financing arrangements between the two companies designed to unlock research and development tax credits available in Australia, the company said.